Hb. Muss et al., ECHINOMYCIN IN RECURRENT AND METASTATIC ENDOMETRIAL CARCINOMA - A PHASE-II TRIAL OF THE GYNECOLOGIC-ONCOLOGY-GROUP, American journal of clinical oncology, 16(6), 1993, pp. 492-493
Twenty-one evaluable patients with recurrent or metastatic endometrial
carcinoma were treated with 1,500 mug/m2 of echinomycin every 3 weeks
. All patients had received prior chemotherapy. There was one complete
response (5%), 95% confidence interval for response is 0.9-22.7%. The
major toxicity was nausea and vomiting which was moderate to severe i
n 42% of patients. Myelosuppression was minimal. Echinomycin, in this
dose and schedule, displays minimal activity in patients with advanced
endometrial carcinoma who have had prior chemotherapy.